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GH treatment increases insulin levels in girls with Turner
syndrome (TS), who are already predisposed to develop dia-
betes mellitus and other risk factors for developing cardio-
vascular disease. Therefore, in the present study, we investi-
gated carbohydrate metabolism and several other risk factors
that may predict development of cardiovascular disease in
girls with TS after discontinuation of long-term GH treatment.
Fifty-six girls, participating in a randomized dose-response
study, were examined before, during, and 6 months after
discontinuing long-term GH treatment with doses of 4 IU/m2d
(0.045 mg/kgd), 6 IU/m2d, or 8 IU/m2d. After a minimum of
4 yr of GH treatment, low-dose micronized 17-estradiol was
given orally. Mean (SD) age at 6 months after discontinuation
of GH treatment was 15.8 (0.9) yr. Mean duration of GH treat-
ment was 8.8 (1.7) yr. Six months after discontinuation of GH
treatment, fasting glucose levels decreased and returned to
pretreatment levels. The area under the curve for glucose
decreased to levels even lower than pretreatment level (P <
0.001). Fasting insulin levels and the area under the curve for
insulin decreased to levels just above pretreatment level (P <
0.001 for both), although being not significantly different from
the control group. No dose-dependent differences among GH
dosage groups were found. At 6 months after discontinuation,
impaired glucose tolerance was present in 1 of 53 girls (2%),
and none of the girls developed diabetes mellitus type 1 or 2.
Compared with pretreatment, the body mass index SD-score
had increased (P < 0.001), and the systolic and diastolic blood
pressure SD-score had decreased significantly at 6 months af-
ter discontinuation of GH treatment (P < 0.001 for both) al-
though remaining above zero (P < 0.001, P < 0.05, and P <
0.005, respectively). Compared with pretreatment, total cho-
lesterol (TC) did not change after discontinuation of GH treat-
ment, whereas the atherogenic index [AI  TC/high-density
lipoprotein cholesterol (TC/HDL-c)] and low-density lipopro-
tein cholesterol (LDL-c) had decreased; and both HDL-c and
triglyceride levels increased (P < 0.001 for AI, LDL-c, and
HDL-c; P < 0.05 for triglyceride). Compared with the control
group, AI, serum TC, and LDL-c levels were significantly lower
(P < 0.001 for all), whereas HDL-c levels were significantly
higher (P < 0.05).
In conclusion, after discontinuation of long-term GH treat-
ment in girls with TS, the GH-induced insulin resistance dis-
appeared, blood pressure decreased but remained higher
than in the normal population, and lipid levels and the AI
changed to more cardio-protective values. (J Clin Endocrinol
Metab 87: 5442–5448, 2002)
ONE OF THE main clinical features of Turner syndrome(TS) is short stature. Although girls with TS are not
GH-deficient (1), GH treatment has been proven to lead to a
considerable height gain in girls with TS in whom treatment
with GH was started at a young age and were treated with
supraphysiological dosages (2, 3). However, because GH
treatment increases insulin levels, several authors have ex-
pressed their concern regarding the long-term effect of GH
treatment in children with a predisposition for diabetes mel-
litus (DM) (4, 5).
Besides DM, girls with TS are also predisposed to develop
cardiovascular disease (CVD). It has even been reported that
CVD is the main cause of their reduced life expectancy (6, 7).
In addition, risk factors for CVD, such as hyperlipidemia,
hypertension, and insulin resistance, occur more often in TS
(7–10).
In the present study, we investigate carbohydrate metab-
olism in girls with TS after discontinuation of long-term GH
treatment with dosage up to 8 IU/m2d (0.090 mg/kgd).
Furthermore, we investigate several factors that may predict
development of CVD, such as blood pressure (BP), body
mass index (BMI), and blood lipid levels.
Subjects and Methods
Study group and treatment regimens
The study group comprised 56 girls with TS who were examined 6
months after discontinuation of GH treatment. Fifty-four children had
an oral glucose tolerance test (OGTT) at 6 months after discontinuation
of GH. All girls had been part of a multicenter GH dose-response study
in The Netherlands, in which 68 girls were included. Inclusion criteria
of the dose-response trial were described previously (11); in short: a
chronological age between 2 and 11 yr, height below the 50th percentile
for healthy Dutch girls, and a normal thyroid function. Of the original
68 girls, 6 girls were not examined at 6 months after discontinuation of
GH treatment, and 6 girls were still treated with GH. Written informed
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consent was obtained from the girls and their parents or custodians. The
study protocol was approved by the ethics committee of each partici-
pating center.
After stratification for chronological age and height sd-score for
chronological age, girls were randomly assigned to group A [4 IU/m2d
(0.045 mg/kgd)], group B (1st yr, 4 IU/m2d; thereafter, 6 IU/m2d),
or group C (1st yr, 4 IU/m2d; 2nd yr, 6 IU/m2d; thereafter, 8 IU/m2d).
Biosynthetic human GH (Norditropin; Novo Nordisk A/S, Bagsvaerd,
Denmark) was given sc once daily. GH treatment was discontinued
when height velocity was less than 1 cm/6 months or when satisfied
with their attained height. After a minimum of 4 yr of GH treatment,
micronized 17-estradiol was given orally to the girls of 12.0 yr and older
(5 g/kg body weightd in the first 2 yr; 7.5 g/kgd in the 3rd yr; and
thereafter, 10 g/kgd). After 2 yr of estrogen treatment, a progestagen
was added (5 mg Duphaston). The estrogen dose was gradually in-
creased to adult level (2 mg) after discontinuation of GH treatment. Five
of the 56 girls had a repaired coarctation without a residual gradient, left
ventricle hypertrophy, or hypertension; 17 girls had a nonstenotic ab-
normal aortic valve; and none of the girls had a renal malformation that
could influence BP. One of the 56 girls, after repair of multiple congenital
cardiac malformations, had a remaining left ventricle hypertrophy,
which could explain her higher BP during and after discontinuation of
GH treatment.
Study protocol
At the start of GH treatment (pretreatment) and every 3 months after
the start of GH treatment, all girls were seen, at their local hospital, for
a physical examination. All underwent an OGTT after overnight fasting
[in the previous 3 d, 100 g of carbohydrate (Fantomalt); oral glucose load
of 1.75 g/kg body weight, maximum of 50 g] at pretreatment, after 4 yr
of GH treatment, and 6 months after discontinuation of GH treatment.
Blood samples were analyzed at 0, 30, 60, 90, 120, 150, and 180 min, for
plasma glucose and insulin levels. In addition, the following variables
were described: 1) Impaired glucose tolerance (IGT) was defined ac-
cording to The Expert Committee on the Diagnosis and Classification of
Diabetes Mellitus (12): the 2-h glucose level more than 7.8 mm (140
mg/dl) and less than 11.1 mm (200 mg/dl). 2) The 3-h area under the
curve (AUC) for time-concentration for glucose and insulin was calcu-
lated using the trapezoidal rule (3). The ratio insulin/glucose at 30 min
and the ratio at 120 min were calculated as an index for relative insulin
resistance. Results were compared with the data of 24 normal adolescent
girls, 14.7 (0.98) yr old, selected on the basis of postpubertal stage
(Tanner breast stage 5) as described by Potau et al. (control group) (13).
Height and BMI [kg BW/(height)2] were expressed as a sd-score for sex
and chronological age (14, 15). Systolic and diastolic BP was determined
four times with a single Dynamap Critikon 1846SX in sitting position
using a cuff size corresponding to arm size. BP was expressed as a
sd-score, using age- and sex-specific reference values (16). A child was
considered normotensive if BP was below the 90th percentile. Additional
blood samples were taken at the start of the study and subsequently
every year, for determination of glycosylated hemoglobin (HbA1c) lev-
els. Serum total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-c), and high-density lipoprotein cholesterol (HDL-c) levels were
determined after overnight fasting at the start, at 4 yr of GH treatment,
and at 6 months after discontinuation of GH treatment. The atherogenic
index (AI) was calculated as the ratio of TC to HDL cholesterol. TC,
HDL-c and LDL-c levels, and AI were compared with those of a Dutch
control group of the same age and sex (17). After centrifugation, all
samples were frozen (20 C) until assayed.
Assays
The plasma glucose level was measured at the local hospital labo-
ratories, and plasma insulin was determined in one laboratory by RIA
(Medgenix, Fleurus, Belgium) as described previously. Control samples
were measured by a comparable RIA (R2  0.988; y  0.397  0.925x)
(13). HbA1c levels and lipid levels were measured in one laboratory as
described elsewhere (4, 11). Lipid levels for the control group were
measured by the same assays in the same laboratory (17). All blood
sample measurements were performed in the same laboratories during
the whole study period.
Statistical analyses
Results were expressed as mean (sd), unless indicated otherwise. For
continuous variables with a skewed distribution, a logarithm-transfor-
mation was used. Differences among the dosage groups were tested by
linear regression analysis, with the variables being age at the start and
two dummy variables for the dosage group. Differences in time among
continuous variables were compared by paired two-sided t test for the
whole group. To test whether variables expressed in sd-score were
different from zero, a one-sample t test was performed. Differences
between the whole TS group and the control group for the carbohydrate
variables were tested by two-sided independent sample t test. All cor-
relations were partial correlations, adjusted for GH dosage. A P value
less than 0.05 was considered significant. All calculations were per-
formed by software from SPSS, Inc. (version 9.0; Chicago, IL).
Results
In Table 1, pretreatment characteristics of the 56 children
are shown. All GH dosage groups had similar pretreatment
characteristics. Mean (sd) age at 6 months after discontinu-
ation of GH treatment was 15.8 (0.9) yr. Mean duration of GH
treatment was 8.8 (1.7) yr. Forty-four of the 56 girls were
treated with GH for 7 yr or longer.
Six months after discontinuation of GH treatment, fasting
glucose levels for the whole group had decreased signifi-
cantly, compared with 4 yr of GH treatment (P 0.01), after
a significant increase from pretreatment to 4 yr of GH treat-
ment (P  0.01), and returned to pretreatment levels (Table
2). Mean glucose levels during OGTT are depicted for groups
A, B, and C in Fig. 1. The 180-min AUC for glucose at 6
months after discontinuation of GH treatment for the whole
group decreased to levels even lower than pretreatment (P
0.001), after a small nonsignificant rise from pretreatment to
4 yr of GH treatment. Fasting glucose levels and the 180-min
AUC for glucose for the whole group were not significantly
different among the GH dosage groups (Table 2). No sig-
nificant differences were found between the whole TS group
at 6 months after discontinuation of GH treatment and the
control group in fasting glucose or 120 min AUC for glucose.
Because the control group had a 120-min OGTT, the 120-min
AUC in the TS group was used to compare data.
Mean insulin levels during OGTT are depicted in Fig. 2 for
groups A, B, and C. Fasting insulin levels (Table 2) and the
AUC for insulin at 6 months after discontinuation of GH
treatment for the whole group had significantly decreased,
compared with 4 yr of GH treatment (P 0.01 after logarithm
transformation, and P  0.001, respectively), after a signif-
icant rise from pretreatment to 4 yr of GH treatment (P 
TABLE 1. Pretreatment variables
Group A Group B Group C
Number of girls 19 17 20
Age at start of GH
treatment
6.5 (1.9) 7.5 (1.9) 6.5 (2.4)
Height SD scorea (normal
girls)
2.8 (0.9) 2.7 (0.8) 2.6 (1.0)
Height SD scorea (TS girls) 0.01 (1.1) 0.2 (0.9) 0.19 (1.1)
Karyotypeb 45,X 16 16 15
other 3 1 5
Data are expressed as mean (SD).
a Height SD score for sex and chronological age in normal girls (15)
and in girls with TS (14) at start of GH treatment.
b Number of girls.
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0.001); but both remained increased, compared with pre-
treatment levels (P 0.001 for both) (Table 2). No significant
differences among GH dosage groups were found for change
in time for fasting insulin levels and change in time for AUC
for insulin. Compared with the control group, the AUC for
insulin at 6 months after discontinuation of GH treatment for
the whole TS group showed no significant difference.
The ratio for insulin to glucose at 30 (30 ratio) and 120
(120 ratio) for the whole group at 6 months after discontin-
uation of GH treatment decreased significantly, compared
with 4 yr of GH treatment (both variables tested after log-
arithm transformation; 30 ratio: P  0.01; 120 ratio: P 
0.001), after an increase in both ratios from pretreatment to
4 yr of GH treatment (P  0.001 for both) (Table 2). Both the
30 ratio and 120 ratio at 6 months after discontinuation of
GH treatment remained above pretreatment values (P 
0.001 for both). No significant differences among GH dosage
groups were found for change in time for both ratio’s.
At 6 months after discontinuation of GH treatment, IGT
was present in 1 of 53 girls (2%). The IGT in this girl was not
present before or during GH treatment. None of the girls
developed DM type 1 or 2.
The HbA1c values for the whole group at 6 months after
discontinuation of GH treatment had significantly de-
creased, compared with 7 yr of GH treatment (P  0.001),
while showing no significant differences among GH dosage
groups. Throughout the years, all individual HbA1c levels
remained within normal range.
From pretreatment to 7 yr of GH treatment, the BMI sd-
score for the whole group had increased significantly [from
–0.02 (0.88) to 0.90 (0.92), P  0.001]. Compared with the
mean BMI for the reference population (zero sd-score), the
BMI sd-score was not significantly different at pretreatment,
but it increased to values significantly above zero (P 0.001)
at 7 yr of GH treatment. At 6 months after discontinuation
of GH treatment, the BMI sd-score had continued to increase
slightly, compared with 7-yr values [1.13 (0.97), P  0.01].
The BMI sd-score at 6 months after discontinuation of GH
treatment and the change in time for BMI sd-score were not
significantly different among GH dosage groups.
From pretreatment to 7 yr of GH treatment, systolic BP for
the whole group did not change significantly, whereas dia-
stolic BP showed a small decrease (P 0.01), both remaining
significantly higher than zero (P  0.001, P  0.05) (Fig. 3).
At 6 months after discontinuation of GH treatment, the sys-
tolic BP sd-score had decreased significantly, compared with
7 yr of GH treatment (P  0.05), while the decrease in dia-
stolic BP sd-score did not reach significance. Compared with
pretreatment, both systolic and diastolic BP sd-scores had
decreased significantly at 6 months after discontinuation of
GH treatment (P  0.001 for both), although BP sd-scores
after discontinuation of GH treatment remained significantly
higher than zero (P 0.05 for both). BP sd-scores at 6 months
after discontinuation of GH treatment were not significantly
different among dosage groups except for the diastolic BP
sd-score between groups B and C (lower in group C: P 
0.05). The changes in time for BP sd-scores, however, were
not significantly different among GH dosage groups. At pre-
treatment, 19 of 53 (36%) of the TS girls had a systolic and/or
diastolic BP above 1.3 sd-score (90th percentile for same
age and sex); at 4 yr, 23 of 55 (42%); at 7 yr of GH treatment,
19 of 44 (43%); and after discontinuation of GH treatment, 14
of 53 (26%). Eleven of the 14 girls who had a BP above the
1.3 sd-score after discontinuation of GH treatment also had
a BP above the1.3 sd-score at pretreatment, and/or at 4 yr,
and/or at 7 yr of GH treatment.
Serum TC and LDL-c levels after 4 yr of GH treatment for
the whole group decreased significantly, compared with pre-
treatment (P 0.001 for all), whereas HDL-c and triglyceride
levels had increased (P  0.001 for both) (Table 3). After
TABLE 2. Carbohydrate data before, during, and after long-term GH treatment
GH Group A(n  19)
Group B
(n  16)
Group C
(n  19)
Whole group
(n  54)
Fasting glucosea (mM) Start 4.4 (0.5) 4.6 (0.4) 4.6 (0.8) 4.5 (0.6)
4 yr 4.8 (0.5) 4.7 (0.6) 5.1 (0.9) 4.9 (0.7)c
Post 4.4 (0.5) 4.7 (0.4) 4.6 (0.7) 4.5 (0.5)d
AUC glucosea (mM  180 min) Start 1072 (184) 1118 (172) 1096 (181) 1095 (177)
4 yr 1072 (122) 1154 (143) 1126 (188) 1116 (155)
Post 953 (111) 975 (132) 962 (134) 963 (124)c,e
Fasting insulinb (mU/l) Start 4 (8) 4 (10) 5 (13) 4.5 (2.2)
4 yr 12 (23) 16 (38) 16 (45) 14.2 (3.3)c
Post 11 (19) 11 (18) 11 (22) 10.7 (2.9)c,d
AUC insulina (mU/l  180 min) Start 3863 (2411) 4858 (3284) 3941 (1626) 4205 (2482)
4 yr 7798 (3355) 14369 (15123) 9733 (3385) 10533 (9094)c
Post 6553 (2468) 5837 (3151) 5987 (2867) 6136 (2791)c,d
Ratio ins/glub 30 min Start 3.5 (10.7) 4.6 (10.2) 3.8 (6.6) 3.9 (7.4)
4 yr 7.4 (13.8) 11.8 (37.6) 9.8 (20.6) 9.4 (21.2)c
Post 7.8 (20.0) 7.1 (23.0) 6.5 (11.3) 7.1 (17.9)c,d
Ratio ins/glub 120 min Start 2.4 (7.5) 3.6 (9.6) 3.3 (6.4) 3.0 (7.5)
4 yr 6.5 (13.2) 8.7 (16.5) 7.6 (13.8) 7.5 (13.5)c
Post 5.6 (8.3) 3.8 (6.1) 4.8 (10.5) 4.7 (9.6)c,e
HbA1ca (% Hb) Start 4.8 (0.5) 4.9 (0.5) 4.8 (0.5) 4.9 (0.5)
7 yr 4.6 (0.5) 4.6 (0.7) 4.6 (0.4) 4.6 (0.5)c
Post 4.3 (0.5) 4.3 (0.5) 4.3 (0.5) 4.3 (0.5)c,e
Data are expressed as a mean (SD) and b geometric mean (90th percentile). AUC, Area under the curve calculated with trapezoid rule; ins/glu,
insulin/glucose.
Paired t test for whole group: c P  0.01 (vs. start); d P  0.01, e P  0.001 (vs. 4 yr).
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discontinuation of GH treatment, TC, LDL-c, but also HDL-c
levels had increased significantly, compared with 4-yr levels
(P  0.001 and P  0.01, respectively), whereas triglyceride
levels decreased significantly (P  0.05). Compared with
pretreatment, TC did not change at 6 months after discon-
tinuation of GH treatment, LDL-c had decreased, and both
HDL-c and triglyceride levels increased (P 0.001 for LDL-c
and HDL-c, P 0.05 for triglyceride). Discontinuation of GH
treatment resulted in a decrease in AI (TC/HDL-c), com-
pared with 4-yr values (P  0.001), but also compared with
pretreatment (P  0.001). The changes in serum lipid levels
were not significantly different among the GH dosage
groups, except for the change in time for group C (decrease
FIG. 1. Mean glucose levels during OGTT for group A (left) and group
B (right) before treatment (black circles), at 4 yr of GH treatment
(black diamonds), at 6 months after discontinuation of treatment
(white triangles), and for the control group (white squares).
FIG. 2. Mean insulin levels during OGTT for group A (left), group B
(middle), and for group C (right) before treatment (black circles), at
4 yr of GH treatment (black diamonds), at 6 months after discontin-
uation of treatment (white triangles), and for the control group (white
squares).
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instead of increase) in TC from pretreatment to 6 months
after discontinuation of GH treatment (group C vs. group A
or B, P 0.01 for both) and a smaller increase in LDL-c from
4 yr of GH treatment to 6 months after discontinuation of
treatment (group C vs. group A or B, P  0.05). Compared
with the control group, serum TC and LDL-c levels were
significantly lower in the whole TS group at 6 months after
discontinuation of GH treatment (P  0.001 for both),
whereas HDL-c levels were significantly higher (P  0.05).
Furthermore, the AI was significantly lower at 6 months after
GH treatment, compared with the control group (after log
transformation, P  0.001).
A significant correlation was found for the whole group
when fasting insulin levels (log transformed) and the AUC
for insulin was correlated with BMI sd-score at 6 months after
discontinuation of GH treatment, after correction for GH
dosage group (r  0.58, P  0.001; r  0.35, P  0.05, re-
spectively). No correlation was found for the whole group
among the 30 ratio, 120 ratio, systolic or diastolic BP sd-
score, TC, AI, or triglyceride levels and BMI sd-score at 6
months after discontinuation of GH treatment. The AI at 6
months after discontinuation of GH treatment, after correc-
tion for GH dosage, did not correlate with fasting insulin
levels, AUC for insulin, or systolic or diastolic BP sd-score at
6 months after discontinuation of GH treatment.
Discussion
In this article, we describe the effect of discontinuation of
long-term GH treatment on glucose and insulin levels, BMI,
BP, and serum lipid levels in girls with TS. We show that both
fasting and stimulated insulin levels, after an increase during
GH treatment, returned to normal after discontinuation. In
addition, we show that after discontinuation of GH treat-
ment, both systolic and diastolic BP and the AI (TC/HDL-c)
had fallen.
Fasting glucose levels increased during GH treatment and
decreased after discontinuation of GH treatment, whereas
stimulated glucose levels showed no change during GH
treatment and decreased after its discontinuation. Further-
more, after ending GH treatment, insulin levels and the in-
dices for relative insulin resistance (30 and 120 ratios for
insulin/glucose) fell but only to a point above pretreatment
levels. Similar results have been found previously in children
with idiopathic short stature and in girls with TS after dis-
continuation of GH treatment (18, 19). Moreover, we show
that stimulated insulin levels after discontinuation were
comparable with normal postpubertal girls. Several studies
have shown that insulin sensitivity decreased during pu-
berty, resulting in an increase in stimulated insulin levels (13,
20, 21). Subsequently, in post puberty, although insulin levels
were decreasing, they were still at a higher level than before
puberty (20). These results might therefore imply that the
reason why insulin levels and the indices for relative insulin
resistance did not return to pretreatment positions was that
our study group was in its postpubertal stage. Another ex-
planation for the higher insulin levels and indices for relative
insulin resistance after discontinuing GH might be the in-
crease in BMI sd-score we found in our study group after
discontinuation of GH treatment. Previous studies have
shown a positive correlation between insulin levels and BMI
in normal children and adults (22, 23). Supporting this ex-
planation, in our study, we found a positive correlation be-
tween BMI sd-score and fasting and stimulated insulin levels
after discontinuation of GH treatment. Several reports, how-
ever, have shown an increased prevalence of insulin resis-
tance and IGT in untreated women with TS (24, 25). There-
fore, the higher insulin levels might also be a result of having
TS. The prevalence of IGT in our study, however, was low
(1 girl).
After discontinuation of GH treatment, we found a de-
crease in BP sd-scores, compared with pretreatment. Because
this decrease has been corrected for age, it is unlikely that age
could explain this decrease. A possible explanation might be
the initiation of estrogen treatment. Confirming this expla-
nation, Gravholt et al. (9) showed that the start of supple-
mentation of natural estrogens, in combination with proge-
stagens in adult women with TS, decreased ambulatory BP.
In another study on adult TS women, however, no change in
FIG. 3. Mean (SD) systolic BP SD-score (A) and diastolic BP SD-score
(B), using age-matched reference values, before GH treatment; at 2,
4, and 7 yr of GH treatment; and at 6 months after discontinuation
of treatment for group A (white bars), group B (gray bars), and for
group C (black bars).
5446 J Clin Endocrinol Metab, December 2002, 87(12):5442–5448 van Pareren et al. • CVD Risk after GH Therapy in TS
 on November 14, 2006 jcem.endojournals.orgDownloaded from 
BP was found after hormone replacement therapy was ini-
tiated (26). Another possible explanation might be a positive
effect of GH treatment on BP, which has been postulated
to occur in children born small for gestational age (27). BP
after discontinuation of GH treatment, however, remained
slightly higher than in girls matched for age. The reason
possibly lies in the fact that having TS is a predisposition for
hypertension (7). The etiology of the predisposition, how-
ever, remains unclear (28). Because we found a decrease in
BP, compared with pretreatment, it is unlikely that GH treat-
ment was responsible for the higher BP.
During the first 4 yr of GH treatment, we show a decrease
in AI, TC, and LDL-c and an increase in HDL-c and triglyc-
eride. Previous studies, studying lipid levels during GH
treatment in TS, showed either similar results during GH
treatment (29, 30) or no effect (31). After discontinuation of
GH treatment, compared with 4-yr lipid levels, TC and
LDL-c levels had increased, compared with the decrease we
found during treatment, whereas triglyceride levels had de-
creased slightly after an increase during GH treatment. Sim-
ilar results were found in reports on the effect of discontin-
uation of GH in GH-deficient adolescents (32, 33), thus
possibly implying a GH effect. HDL-c levels after discon-
tinuation of GH treatment, however, showed a further in-
crease. A possible explanation for this could be the induction
of puberty with natural estrogens and dydrogestagen, which
has been shown to lead to an increase in HDL-c (34). A second
explanation for the increase in TC, LDL-c, and HDL-c after
discontinuing GH might be the age effect, because it has been
established that after puberty, TC, LDL-c, and HDL-c in-
crease with age (35, 36). Interestingly, when we compared
lipid levels after discontinuation of GH treatment, to a nor-
mal control group of similar age, we found that TC, LDL-c,
and AI levels were lower and HDL-c levels were higher in
our study group. This indicated that, whereas previous re-
ports on lipid levels in untreated girls and women with TS
have shown conflicting results regarding the prevalence of
dyslipidemia (8, 10, 37, 38), in our study group, after long-
term GH treatment, we found no evidence of dyslipidemia.
Because several studies have found that women with TS
are predisposed to develop CVD (6, 7), and several risk
factors for CVD (such as high BP, dyslipidemia, and ab-
dominal obesity) have been found to be more prevalent in
TS, we analyzed our data for clustering of these CVD risk
factors by way of correlations. Although, after discontin-
uation of GH treatment, we found a positive correlation
between BMI sd-score and insulin levels, we could not
detect any other correlations among the risk factors. In
contrast, in a study on the effect of discontinuation of GH
treatment in children of similar age, but born small for
gestational age, a positive correlation among the AI, BMI
sd-score, systolic and diastolic BP sd-score, and fasting
insulin was found (39). The lack of correlation among the
cardiovascular risk factors in our group with TS, however,
suggested that, in this group, no clustering of risk factors
was present. Because a clustering of risk factors potentially
increases the risk for CVD (40), not only follow-up of all
risk factors but also evaluation of clustering should take
place in the future. Though we did not find evidence of
clustering, we did find a positive correlation between in-
sulin resistance and BMI. Although this relationship is also
found in normal children (23, 41), insulin resistance does
predispose for the development of DM type 2. We would
therefore urge clinicians to do their utmost to prevent
further weight gain in girls and women with TS.
In conclusion, after discontinuation of long-term GH treat-
ment in girls with TS, the GH-induced insulin resistance
disappeared. BP decreased both during and after discontin-
uation of GH treatment, but remained higher than in the
normal population, whereas lipid levels and the AI after
discontinuation of GH treatment were more beneficial, re-
garding the development of CVD, than in a normal control
group.
TABLE 3. Lipid levels before, during, and after GH treatment
GH Group A(n  19)
Group B
(n  17)
Group C
(n  20)
Whole group
(n  56)
Controlsa
(n  703)
TCb (mM) Start 4.0 (0.7) 4.3 (0.8) 4.5 (0.9) 4.3 (0.8)
4 yr 3.8 (0.7) 4.1 (0.8) 4.0 (0.7) 4.0 (0.7)e
Post 4.1 (0.8) 4.5 (0.7) 4.1 (0.6)j 4.2 (0.7)e 4.7 (0.7)l
HDL-cb (mM) Start 0.6 (0.1) 0.7 (0.1) 0.9 (0.2) 0.7 (0.2)
4 yr 1.0 (0.3) 1.0 (0.2) 1.2 (0.3) 1.1 (0.3)e
Post 1.3 (0.3) 1.4 (0.3) 1.5 (0.4) 1.4 (0.3)e,h 1.3 (0.3)k
LDL-cb (mM) Start 2.6 (0.7) 2.9 (0.9) 2.9 (1.0) 2.8 (0.9)
4 yr 1.9 (0.7) 2.1 (0.6) 2.2 (0.7) 2.1 (0.7)e
Post 2.1 (0.6) 2.5 (0.6) 2.2 (0.6)i 2.3 (0.6)e,g 2.9 (0.7)l
Triglc (mM) Start 1.0 (1.5) 0.9 (1.5) 0.9 (2.1) 0.9 (1.6)
4 yr 1.3 (3.2) 1.2 (2.6) 1.2 (2.2) 1.2 (2.5)e
Post 1.3 (2.8) 1.0 (1.7) 0.9 (1.7) 1.1 (1.9)d,f
Atherogenic indexc Start 7.1 (8.6) 6.4 (8.1) 4.9 (6.8) 6.0 (8.2)
4 yr 4.0 (5.6) 4.0 (5.6) 3.2 (4.6) 3.7 (5.5)e
Post 3.2 (4.0) 3.2 (4.3) 2.8 (3.8) 3.0 (4.0)e,h 3.6 (4.8)l
a Dutch control group of same age and sex (17).
Data are expressed as b mean (SD) and c geometric mean (90th percentile). Trigl, Triglycerides. Atherogenic index  TC/HDL-c.
Paired t test for change in time for whole group: d P  0.05, e P  0.001 (vs. start); f P  0.05, g P  0.01, h P  0.001 (vs. 4 yr).
Linear regression analysis for change from 4 yr of GH: i P  0.05 (group C vs. groups A and B, corrected for age at start); for change from
start: j P  0.01 (group C vs. groups A and B, corrected for age at start); for control group vs. whole TS group: k P  0.05, l P  0.001 (corrected
for dosage group and age).
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